The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients

BACKGROUND: Few data are available regarding the treatment of metastatic colorectal cancer elderly patients with anti-EGFR agents in combination with chemotherapy. FOLFOX plus panitumumab is a standard first-line option for RAS wild-type metastatic colorectal cancer. Slight adjustments in chemo-dosa...

Descripción completa

Detalles Bibliográficos
Autores principales: Battaglin, Francesca, Schirripa, Marta, Buggin, Federica, Pietrantonio, Filippo, Morano, Federica, Boscolo, Giorgia, Tonini, Giuseppe, Lutrino, Eufemia Stefania, Lucchetti, Jessica, Salvatore, Lisa, Passardi, Alessandro, Cremolini, Chiara, Arnoldi, Ermenegildo, Scartozzi, Mario, Pella, Nicoletta, Boni, Luca, Bergamo, Francesca, Zagonel, Vittorina, Loupakis, Fotios, Lonardi, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784655/
https://www.ncbi.nlm.nih.gov/pubmed/29370781
http://dx.doi.org/10.1186/s12885-018-4001-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784655/
https://www.ncbi.nlm.nih.gov/pubmed/29370781
http://dx.doi.org/10.1186/s12885-018-4001-x

Ejemplares similares